GlucoTrack (Nasdaq:GCTK) announced today that it appointed Mark Tapsak as its vice president of sensor technology.
Tapsak, a veteran of more than 25 years in the diabetes industry, joins the company, effective immediately. His experience includes time spent as a medical device research scientist. He focused on polymer synthesis, polymer characterization, medical device design and intellectual property.
Get the full story at our sister site, Drug Delivery Business News.
GlucoTrack (Nasdaq:GCTK) announced that it plans to expand its product pipeline with a R&D program for a long-term continuous glucose monitor (CGM).
Rutherford, New Jersey-based GlucoTrack said it recently required related IP. It now intends to develop a long-term, implantable glucose management platform for the type 1 diabetes market.
Get the full story at our sister site, Drug Delivery Business News.
GlucoTrack (Nasdaq:GCTK) announced today that its second-generation glucose monitor device has shown promising results in analyses.
Rutherford, New Jersey-based GlucoTrack — formerly known as Integrity Applications (Nasdaq:IGAP) — earlier this year completed lab testing of the non-invasive GlucoTrack 2.0 clinical prototype system and has observed better-than-expected accuracy and performance with the technology.
Get the full story at our sister site, Drug Delivery Business News.
Integrity Applications (Nasdaq:IGAP) announced today that it completed the change of its corporate name to GlucoTrack.
Rutherford, New Jersey-based GlucoTrack confirmed the change of its ticker symbol on the Nasdaq capital market to “GCTK,” which was made effective at the commencement of trading today, March 14, 2022.
Get the full story at our sister site, Drug Delivery Business News.